A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Solid Tumors

Interventions

DRUG: PF-07220060 + PF-07104091 combination dose escalation
DRUG: PF-07220060 + PF-07104091 combination dose escalation
DRUG: PF-07220060 + PF-07104091 combination dose escalation
DRUG: PF-07220060 + PF-07104091 combination dose escalation
DRUG: PF-07220060 + PF-07104091 combination dose escalation
DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion
DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion
DRUG: PF-07104091 + PF-07220060 + letrozole dose expansion
DRUG: PF-07220060 + PF-07104091 combination dose escalation
DRUG: PF-07220060 + PF-07104091 combination dose escalation
DRUG: PF-07220060 + PF-07104091 combination dose escalation

Sponsor

Pfizer